NervGen Financial Statements From 2010 to 2024
| NGENF Stock | USD 1.85 0.06 3.35% |
Check NervGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NervGen Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . NervGen financial statements analysis is a perfect complement when working with NervGen Pharma Valuation or Volatility modules.
NervGen |
NervGen Pharma Corp OTC Stock Return On Equity Analysis
NervGen Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NervGen Pharma Return On Equity | -1.42 |
Most of NervGen Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NervGen Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, NervGen Pharma Corp has a Return On Equity of -1.4176. This is 94.09% lower than that of the Healthcare sector and 96.11% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
NervGen Pharma Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NervGen Pharma's current stock value. Our valuation model uses many indicators to compare NervGen Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NervGen Pharma competition to find correlations between indicators driving NervGen Pharma's intrinsic value. More Info.NervGen Pharma Corp is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NervGen Pharma's earnings, one of the primary drivers of an investment's value.About NervGen Pharma Financial Statements
NervGen Pharma stakeholders use historical fundamental indicators, such as NervGen Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although NervGen Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in NervGen Pharma's assets and liabilities are reflected in the revenues and expenses on NervGen Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NervGen Pharma Corp. Please read more on our technical analysis and fundamental analysis pages.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.